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Nuclear factor-B (NFB) is an inducible transcription factor
that plays a key role in regulating the expression of a wide range of
immune and inflammatory response genes. The activity of NFB is
controlled at multiple levels, including cytoplasmic retention with
inhibitor of B (IB) proteins in the basal state. Persistent activa-
tion of the transcription factor is seen in numerous chronic inflam-
matory disease states, and we have previously demonstrated sus-
tained activation of NFB in human glial cells upon stimulation
with interleukin (IL)-1. In these cells, NFB retains DNA binding
activity for up to 72 h despite the presence of resynthesized IB
and in the absence of IB. Here we characterized the apparent
inability of newly synthesized IB to terminate activation ofNFB
in glial cells.We showed unexpectedly that newly synthesized IB
can enter the nucleus, interact with the NFB subunit p65, and
export it to the cytoplasm. However, in vitro analysis of enzyme
activity demonstrates that IL-1 causes the long term activation of
the IB kinase complex leading to chronic phosphorylation of the
newly synthesized IB signal response domain andpersistent acti-
vation of NFB. Such sustained activation of NFB is dependent on
the continuous presence and activity of IL-1. Interestingly, the
sustained nature of NFB activity is promoter type-specific. Chro-
matin immunoprecipitation studies revealed that p65 is detected at
the promoters of both intercellular adhesion molecule-1 and IL-8
1h following IL-1 stimulationbut is only foundat the latter at 24h.
The functional significance of this finding is indicated by the tran-
sient induction of intercellular adhesion molecule-1 mRNA, but
more sustained induction of IL-8 expression, by IL-1. These stud-
ies thus demonstrated that persistent IL-1 signaling causes sus-
tained activation of NFB in a promoter-specific manner in human
glial cells, leading to prolonged induction of selective pro-inflam-
matory genes. This is likely to make a key contribution to chronic
inflammatory conditions of the brain.
Nuclear factor B (NFB)2 is an inducible transcription factor that
plays a key role in regulating the expression of numerous immune and
inflammatory response genes (1, 2). It is a dimeric factor consisting of
subunits from the Rel family of proteins, some members of which are
transcriptionally active (p65, c-Rel, and RelB), although others lack
transactivation domains (p50 and p52) (3). The members of the family
share a conserved region termed the Rel homology domain, containing
the dimerization and site-specific DNA binding domains as well as the
nuclear localization signal (NLS) (4). The activity of NFB is controlled
at multiple levels, most notably by regulation of its subcellular localiza-
tion. In resting cells, NFB is retained in the cytoplasm through its
interaction with inhibitor of B (IB) proteins. The most extensively
studied members of this family are IB and IB. They associate with
NFB via a conserved ankyrin repeat domain. By interacting with the
Rel homology domain, IB serves to occlude the DNA binding domain
and one (IB) or both (IB) NLSs of NFB (5, 6).
Activators of NFB include pro-inflammatory cytokines, bacterial
and viral products, and UV light (2). Exposure of cells to this diverse
range of stimuli results in a commonmechanism of NFB activation. It
is mediated by IB kinase (IKK) complex phosphorylation of the N
terminus of IB on two specific serines, e.g. Ser-32 and Ser-36 on IB
(7). The IKK complex consists of a regulatory subunit, IKK, and two
catalytic subunits IKK and IKK, the latter being most important for
signaling from pro-inflammatory cytokines. The phospho-IB protein
is then polyubiquitinated by the SCF-TrCP ubiquitin ligase complex,
which in turn tags it for degradation by the 26 S proteasome (8). With
theNLS andDNAbinding domains unmasked,NFB can translocate to
the nucleus and bind to the B sites in the promoters of its target genes.
IB and IB differ considerably in their degradation profile and activ-
ity (9). All known inducers of NFB cause IB degradation, and IB
gene expression is then rapidly induced by NFB (10). Free IB can
enter the nucleus, remove NFB from DNA, and export it back to the
cytoplasm (11). A leucine-rich nuclear export sequence in the C-termi-
nal region of IB is responsible for this function by recognizing the
nuclear export receptorCRM1 (12). This inducible autoregulatory feed-
backmechanism accounts for the transient nature ofNFB activation in
response to certain agents. However, long term activation of NFB can
occur in a cell type- and stimulus-dependent manner. Those stimuli
that induce this persistent activation cause degradation of IB in addi-
tion to IB (13).
Sustained activation ofNFB is associatedwithmany chronic inflam-
matory disease states such asmultiple sclerosis (MS), where the entry of
activated T-lymphocytes into the central nervous system (CNS) is a key
pathogenic step (14–16). The repertoire of pro-inflammatory genes
expressed upon NFB activation includes interleukin-8 (IL-8), a CXC
chemokine primarily known for its chemoattractant effects on neutro-
phils, and intercellular cell adhesionmolecule-1 (ICAM-1), an adhesion
molecule of the immunoglobulin superfamily (17–19). These proteins
play an important role in the transendothelial migration of T-lympho-
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cytes required to breach the specialized vasculature separating the CNS
from the peripheral circulation, the blood-brain barrier (20). The
expression levels of IL-8 and ICAM-1 are elevated in MS and experi-
mental allergic encephalitis (EAE), an animal model of MS (21, 22).
Furthermore, both are expressed by astrocytes, a resident CNS cell that
directly underlies the blood-brain barrier (23, 24). This group has pre-
viously shown that interleukin-1 (IL-1) stimulation of 1321N1 astro-
cytoma, a model astrocyte cell system, results in persistent, long term
activation of NFB (25). Analysis of the accompanying IB degradation
profile revealed that IB was transiently degraded and rapidly resyn-
thesized, whereas disappearance of IBwas sustained. This signified a
notable departure from other models of long term NFB activation. In
pre-B cells treated with LPS, the initial degradation of IB is followed
by its resynthesis in a hypophosphorylated form. This form of the pro-
tein can bind to NFB but does not inhibit nuclear translocation or
binding to target promoters. Furthermore, although hypophosphoryl-
ated IB remains bound, IB cannot gain access to NFB to termi-
nate transcriptional activation (26). However, in the case of astrocytes,
IL-1 causes sustained activation of NFB under conditions where
IB is resynthesized and IB is absent. This study thus explored the
apparent inability of IL-1-induced IB to terminate sustained activa-
tion of NFB in human astrocytes.
We show that global NFB activation is sustained despite the ability
of resynthesized IB to enter the nucleus, interact with NFB subunit
p65, and return it to the cytoplasm in IL-1-treated astrocytes. This is
because of persistent IL-1-dependent activation of the IKK complex
and subsequent phosphorylation and degradation of IB, leading to
continuous activation of NFB. Furthermore, analysis of the IL-8 and
ICAM-1 promoters by chromatin immunoprecipitation studies reveals
that the sustained activation of NFB is a not a universal feature at all
promoters of NFB-responsive genes. This study advances our appre-
ciation of themechanism regulating the temporal activation ofNFB by
pro-inflammatory cytokines in astrocytes, and more importantly dem-
onstrates that its sustained activation occurs only in the context of spe-
cific promoters. Such findings increase our understanding of themolec-
ular basis underlying the chronic inflammatory condition of the brain.
EXPERIMENTAL PROCEDURES
Materials—The human astrocytoma cell line 1321N1 was obtained
from the European Collection of Animal Cell Cultures (Salisbury, UK).
Dulbecco’s modified Eagle’s medium, fetal calf serum, penicillin/strep-
tomycin, and trypsin were from Invitrogen. Human recombinant IL-1
and recombinant IL-1 receptor antagonist were purchased from R & D
Systems Europe (Oxon, UK). T4 polynucleotide kinase and the 22-bp
oligonucleotide containing the NF-B consensus sequence (under-
lined) (5-AGTTGAGGGGACTTTCCCAGGC-3) were supplied by
Promega (Madison, WI). [-32P]ATP was purchased from Amersham
Biosciences. Rabbit polyclonal antibodies against IB (sc-203), IB
(sc-945), p65 (sc-372), and protein A/G-agarose (sc-2003) were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse
monoclonal against phospho-IB (Ser-32/36) and rabbit polyclonal
antibody against IKKwere purchased from Cell Signaling Technology
(MA01915). Texas Red-conjugated anti-rabbit polyclonal antibody was
obtained from Molecular Probes (OR97402). Anti--actin mouse
monoclonal antibody, MG132, leptomycin B, and cycloheximide were
purchased from Sigma. Primers and probes for quantitative real time
analysis of ICAM-1 (Hs00164932_m1), IL-8 (4309885P), and 18 S rRNA
(4310893E) were from Applied Biosystems (CA94404). The C-terminal
histidine-tagged recombinant form of IB was a gift from Helmut
Sparrer (Novartis Pharma AG, Switzerland) and has been described
previously (27).
Cell Culture—The human astrocytoma cell line, 1321N1, was cul-
tured in Dulbecco’s modified Eagle’s medium supplemented with 100
units/ml penicillin, 100 g/ml streptomycin, and 10% (v/v) of fetal calf
serum. Cells weremaintained at 37 °C in a humidified atmosphere of 5%
CO2. All cells were passaged using 1% (w/v) of trypsin in PBS. IL-1
stimulation was performed on cells in serum-containing medium at
37 °C for all experiments.
Generation of Cell Extracts—1321N1 astrocytomas were seeded into
25-cm2 flasks (5 ml; 2  105 cells/ml) and allowed to adhere for 72 h
before stimulation. Cells were exposed to IL-1 for various times. Stim-
ulation was terminated by removal of medium followed by washing of
the adherent cells with 3 ml of ice-cold PBS. For preparation of subcel-
lular fractions, washed cells were scraped into 1 ml of hypotonic buffer
(10mMHEPES-NaOHbuffer, pH 7.9, containing 1.5mMMgCl2, 10mM
KCl, 0.5 mM DTT, and 0.5 mM PMSF). Cells were pelleted in hypotonic
buffer by centrifugation at 20,000 g for 10min andwere then lysed for
10 min on ice in hypotonic buffer (35 l) containing 0.1% (v/v) of Non-
idet P-40. Lysates were centrifuged at 20,000 g for 10min. The result-
ing supernatants constituted cytosolic extracts and were removed to
new minifuge tubes and stored at 20 °C. The resulting pellets were
resuspended in 20 mMHEPES-NaOH buffer, pH 7.9 (25l), containing
420mMNaCl, 1.5mMMgCl2, 0.2mMEDTA, 25% (w/v) glycerol, and 0.5
mM PMSF and incubated for 15 min on ice. Incubations were then
centrifuged at 20,000  g for 10 min, and the supernatants were
removed into 10 mM HEPES-NaOH buffer, pH 7.9 (75 l), containing
50 mM KCl, 0.2 mM EDTA, 20% (w/v) glycerol, 0.5 mM PMSF, and 0.5
mM DTT. Such samples constituted nuclear extracts. All of the above
steps were carried out at 4 °C. Protein concentrations of the cytosolic
and nuclear extracts were determined by the method of Bradford (28).
For the generation of whole cell extracts, cells were scraped into 1 ml of
PBS before being pelleted by centrifugation at 20,000  g for 10 min.
After discarding the supernatant, cells were resuspended in sample
buffer (62.5 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% glycerol, 50 mM
DTT, 0.01% (w/v) bromphenol blue; 100 l per sample) and incubated
on ice for 10 min. Resuspended cells were then boiled for 5 min. Cell
debris was pelleted by further centrifugation at 20,000  g for 10 min.
The supernatant containing the cell extract was removed to fresh
Eppendorf tubes.
ElectrophoreticMobility Shift Assay—Nuclear extracts (10g of pro-
tein) were incubated with 30,000 dpm of a 22-bp oligonucleotide con-
taining the NF-B consensus sequence that had been labeled previously
with [-32P]ATP (10 mCi/mmol) by T4 polynucleotide kinase (29).
Incubations were performed for 30 min at room temperature in 10 mM
Tris-HCl buffer, pH 7.5, containing 100 mM NaCl, 1 mM EDTA, 5 mM
DTT, 4% (w/v) glycerol, 4g of poly(dI-dC), and 1mg/ml nuclease-free
bovine serum albumin. In the supershift analysis, polyclonal antibody (1
g) against the NF-B subunit p65 was added to the extracts and incu-
bated for 30min on ice prior to incubationwith labeled oligonucleotide.
All incubations were subjected to electrophoresis on 4% nondena-
turing polyacrylamide gels, which were subsequently dried and
autoradiographed.
Western Immunoblotting—Cytosolic extracts (20 g of protein) in
2 sample buffer (0.125 M Tris-HCl buffer, pH 6.8, containing 20%
(w/v) glycerol, 4% (w/v) of SDS, 1.4 M 2--mercaptoethanol, and
0.0025% (w/v) bromphenol blue) or whole cell extracts (20 l) were
boiled for 5min prior to loading. Extracts were separated by SDS-PAGE
using a 12% (w/v) resolving gel, and proteins were transferred electro-
phoretically to nitrocellulose. Immunodetection of proteins was con-
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ducted as described previously (25). Blots were blocked in 20 mM Tris-
HCl buffer, pH 7.5, containing 0.15 M NaCl (TBS) and 5% (w/v)
powdered milk (Marvel). Incubation with primary mouse monoclonal
anti-phospho-IB (Ser-32/36) antibody (1:2000 dilution) was per-
formed overnight at 4 °C, although incubations with primary antibodies
against p65, IB, or IB (all 1 g/ml) were for 2 h at room tempera-
ture. Horseradish peroxidase-conjugated sheep anti-rabbit IgG and
horseradish peroxidase-conjugated goat anti-mouse IgG (both from
Upstate) were used at concentrations of 1 and 0.5 g/ml respectively.
Immunoreactive bands were detected using the ECL detection system
from Pierce according to the instructions of the manufacturers.
Immunofluorescence—Cells were seeded in 4-well chamber slides
(Lab-Tek) and grown to confluency. Following the appropriate treat-
ment the mediumwas removed, and cells were washed once in ice-cold
PBS. For detection of endogenous p65, cells were first fixed with 3.7%
(v/v) paraformaldehyde in PBS (500l per chamber) for 20min at room
temperature. Cells were then washed twice with PBS, before being per-
meabilized by incubation with 0.2% (v/v) Triton-X-100 (in PBS) for 30
min on an orbital shaker at room temperature. For detection of IB,
cells were incubated for 10 min at 20 °C with a 1:1 mixture of 100%
methanol and acetone (500 l per chamber) after the initial PBS wash.
This served to both fix and permeabilize the cells. After the suitable
fixation/permeabilization step, cells were again washed twice with PBS.
This was followed by blocking the cells in 0.5% bovine serum albumin/
PBS for 20 min at room temperature. After further washes, primary
antibody was added (150 l per well; IB or p65 rabbit polyclonal
antibody at aworking concentration of 2g/ml), and the chamber slides
were placed at 4 °C with rocking overnight. Cells were next incubated
with Texas Red-conjugated goat anti-rabbit antibody (10 g/ml; 150 l
per well), and the chamber slides were incubated for 1 h in the dark at
room temperature with rocking. Cells were washed twice with PBS
before beingmountedwith Slowfade antifade reagent (DAPI containing
medium (1.5 g/ml)) (Molecular Probes, Inc.). Confocal images were
captured using the63 objective (oil immersion) on the UV Zeiss 510
Meta System laser scanning microscope equipped with the appropriate
filter sets and analyzed using the LSM 5 browser imaging software.
Co-immunoprecipitation—Cells were seeded in 6-well plates, grown
to confluency, and treated with or without IL-1 for the various time
periods. Stimulation was terminated by the removal of medium. Cells
were washed once with ice-cold PBS, scraped into 1 ml of PBS, and
pelleted by centrifugation at 20,000  g for 10 min at 4 °C. Cells were
lysed by incubation with 50 mM Tris-HCl, pH 7.5, containing 150 mM
NaCl, 0.5% Igepal, 50 mM NaF, 1 mM Na3VO4, 1 mM DTT, and 1 mM
PMSF (500 l per sample). 50 l of supernatant was retained for West-
ern blot analysis, and the remainder was used for immunoprecipitation.
Lysates were precleared by incubation with 1g of IgG antibody and 10
l of protein A/G-agarose for 30 min. Anti-p65 antibody (1 g) was
added to precleared lysates and incubated overnight at 4 °C with rock-
ing. This was followed by the addition of protein A/G-agarose (20l per
sample). Incubations were placed at 4 °C with rocking for 1 h. Immuno-
precipitates were collected by centrifugation, and the beads were then
washed four times with lysis buffer. The pellet was resuspended in 2
sample buffer. Samples were then boiled for 5 min before analysis by
SDS-PAGE and Western immunoblotting for p65 and IB.
In Vitro Kinase Assay—Cells were seeded in 6-well plates, cultured
for 72 h, and treated with or without IL-1 for the various time periods.
Stimulation was terminated by the removal of medium. Cells were
washed oncewith ice-cold PBS, scraped into 1ml of PBS, and pelleted by
centrifugation at 20,000  g for 10 min at 4 °C. The supernatant was
discarded, and the pellet was resuspended in lysis buffer (20mMHEPES,
pH 7.5, containing 1% Igepal, 0.1mMEDTA, 0.1mMEGTA, 10mMKCl,
2 mM DTT, 10 mM MgCl2, 50 mM NaCl, 100 M Na3VO4, and 20 mM
-glycerol phosphate). Cells were incubated on ice for 10 min, after
which the lysates were centrifuged at 20,000 g for 10 min at 4 °C. The
resulting supernatantwas transferred to a newmicrocentrifuge tube. 1.5
l of rabbit polyclonal anti-IKK antibody was added, and the incuba-
tions were placed on a roller at 4 °C overnight. A 50% slurry comprising
equal volumes of dry protein G-Sepharose beads (Sigma) and lysis
buffer was next added (35 l per sample). The incubations were placed
on a roller at 4 °C for 1 h. The immunoprecipitates were pelleted by
centrifugation at 1000 g for 2min at 4 °C. The beadswere thenwashed
twice in lysis buffer and a further three times in kinase buffer (20 mM
HEPES, pH 7.5, containing 2mMDTT, 10mMMgCl2, 50mMNaCl, 100
M Na3VO4, and 20 mM -glycerol phosphate). After each wash, the
beads were pelleted by centrifugation at 1000 g for 2min. The washes
and subsequent centrifugation steps were performed at 4 °C. After the
final wash the beads were drained dry. The beads were then incubated
for 45 min at room temperature with kinase buffer including 1 g of
recombinant IB and 20 M ATP per sample. Following addition of
sample buffer, samples were boiled for 5 min and subjected to SDS-
PAGE and Western immunoblotting to detect phospho-IB.
Chromatin Immunoprecipitation—1321N1 astrocytoma cells were
grown to confluency in 90-mm dishes and stimulated with IL-1 (10
ng/ml) for the appropriate time period. Chromatin immunoprecipita-
tion assays were performed as described previously with some modifi-
cations (30). Following stimulation cells were cross-linked with 1%
formaldehyde for 10 min at 37 °C. Isolated nuclei were subjected to
seven 10-s sonication pulses from a Sanyo/MES Soniprep 150 at one-
third of total power. Separate aliquots from each chromatin preparation
were incubated overnight at 4 °C with anti-p65 antibody and rabbit IgG
antibody. An aliquot was also retained as an input sample to normalize
PCRs and analyze shearing efficiency. Chromatin used had an average
size of 750 bp. After reversion of cross-links by overnight incubation at
65 °C, DNAwas extracted using the QIAquick purification kit (Qiagen)
according to the manufacturer’s instructions.
StandardPCRwasperformedusing1l (3%of total)of templateDNA,
500 nM primers, and 0.2 units of Taq DNA polymerase (Invitrogen) per
50-l reaction. Quantitative real time PCRs were performed in duplicate
with 2l of templateDNA, 50 nMprimers, and the SYBRGreen Jumpstart
TaqReadymix (Sigma) ina total volumeof20l, using theMx3000PQPCR
System (Stratagene). Dissociation curve analysis and gel electrophoresis of
the final products confirmed that only the expected specific amplicon of
correct size was generated for each target promoter. Real time PCR data
analysis was performed as described previously (31). Results for each treat-
ment are expressed as fold differences between DNA enrichment in the
p65-ChIP sample relative to IgG-ChIP sample. The sequences of primers
used are as follows: ICAM-1, 5-CTCCACTCTCCGGGGAAGTTG-3
and 5-GCTGCAGTTATTTCCGGACTGAC-3; IL-8, 5-GGAAGT-
GTGATGACTCAGGTTTGC-3 and 5-GATGGTTCCTTCCGGTG-
GTTTCTTC-3; andGAPDH, 5-CTACTAGCGGTTTTACGGGCG-3
and 5-TCGAACAGGAGGAGCAGAGAGCGA-3.
Quantitative Real Time PCRAnalysis of ICAM-1 and IL-8 Expression—
1321N1 astrocytomas (2 105 cells/ml) were plated into 6-well plates and
grown for 48 h. Cells were treated with IL-1 (10 ng/ml) for various time
periods. Cells were washed with PBS, and RNA was extracted using Tri-
Reagent (Sigma). After DNase I digestion, cDNAwas generated from nor-
malized RNA using Superscript II reverse transcriptase. Samples were
assayed by quantitative real time PCR for levels of ICAM-1 and IL-8 cDNA
using the ABI PRISM 7900HT thermal cycler. Reactions were performed
using pre-validated primers and probes (Applied Biosystems).
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RESULTS
IL-1 Stimulates the Rapid and Persistent Activation of NFB in
Astrocytes—To confirm and characterize the sustained activation of
NFB by IL-1 in astrocytes, 1321N1 astrocytomaswere treatedwith or
without IL-1 for various time periods. Nuclear extracts were gener-
ated, and the presence of NFB-DNA binding activity was assessed by
EMSA (Fig. 1A). A low level of basal NFB activation was detected in
unstimulated cells. Treatment with IL-1 induced activation of NFB,
observed as the increased presence of a complex of slow electrophoretic
mobility. Activation was rapid and sustained, detectable at 5 min, peak-
ing at 30min butwith significant levels of complex remaining for at least
24 h. Previous studies on this cell type had demonstrated that p65/p50
heterodimers and p65/p65 homodimers display DNA binding activity
after 1 h of stimulation with IL-1 (25). To address whether the later
phase complexesmight be capable of promoting transcription, the com-
plexes were assessed by supershift analysis for the presence of the most
common transactivatingNFB subunit, p65.Nuclear extracts fromcells
treated with or without IL-1 for 24 h were incubated with antisera
against p65, prior to EMSA (Fig. 1B). The IL-1-induced complex was
unaffected by preincubation with the nonimmune IgG isotype control.
In contrast, anti-p65 antibody caused the appearance of a complex of
slow electrophoretic mobility, which coincided with a significant
decrease in the levels of the IL-1-induced complex. It is therefore likely
that the composition of NFB detected throughout the 24-h period was
unaltered. The consistent electrophoretic mobility of the IL-1-in-
duced NFB-DNA complexes over time in Fig. 1A supports this prop-
osition. This demonstrates that IL-1 stimulation causes the persistent
activation of a form of NFB in glial cells that has transactivation
potential.
The degradation profile of the IB proteins was next investigated.
Cytosolic extracts from unstimulated and IL-1-treated cells were
probed for IB and IB byWestern immunoblotting (Fig. 1C). IL-1
caused a transient degradation of IB, with a decrease evident at 30
min but returning to control levels by 1 h. In contrast, IB was
degraded with slower kinetics, disappearing by 1 h. This slower rate of
proteolysis has been observed in numerous cell types. It has been pro-
posed that although the same degradation pathway is utilized, IB is a
poorer substrate for IKK-mediated phosphorylation and polyubiquiti-
nation by SCF-TrCP (32). Also, unlike IB, IB protein failed to
manifest at detectable levels up to 24 h post-IL-1 stimulation. This
clearly eliminated the possibility that IB was resynthesized in a
hypophosphorylated form and acting as a molecular chaperone to sus-
tain NFB activity. Given the absence of IB at later time points of
post-IL-1 stimulation, we next assessed the apparent failure of newly
synthesized IB to terminate the activation of NFB.More specifically
the ability of newly synthesized IB to translocate to the nucleus and
bind to p65 was probed.
Resynthesized IB Can Enter the Nucleus and Interact with NFB
Following IL-1 Treatment of Glial Cells—CRM1-dependent nuclear
export of IB is inhibited by leptomycin B (LMB) (33). Thus, to facil-
itate an investigation into whether IB, resynthesized after IL-1
treatment, can enter the nucleus of 1321N1 astrocytoma, cells were
treated with IL-1 for 30 min to deplete existing IB stocks before
addition of LMB for a further 2.5 h. The subcellular localization of IB
was therefore assessed after a total of 3 h of stimulation in the presence
or absence of IL-1. The ability of newly synthesized IB to enter the
nucleus would be indicated by the nuclear accumulation of IB under
conditions where its export was blocked. Cytoplasmic and nuclear
extracts were prepared, and Western immunoblotting was performed
to examine the subcellular localization of IB (Fig. 2A). IB was
detected in both compartments in astrocytes treated with or without
IL-1, but considerably higher levels were observed in the cytoplasm
(Fig. 2A, lanes 1–4). In unstimulated cells, LMB treatment caused the
accumulation of IB in the nucleus (Fig. 2A, lane 6). This most likely
represents NFB-complexed IB undergoing nucleocytoplasmic
shuttling that becomes sequestered in the nucleus following inhibition
of CRM1-dependent nuclear export. Resynthesized IB also accumu-
lates in the nucleus of IL-1-treated cells in response to LMB (Fig. 2A,
lane 8), indicating that newly formed IB can enter the nucleus. This
was further confirmed by confocal microscopy-based detection of
endogenous IB using anti-IB rabbit polyclonal antibody andTexas
Red-conjugated anti-rabbit secondary antibody. Nuclear chromatin
was stained with DAPI. Untreated cells, or cells treated with IL-1 for
3 h, showed predominant cytoplasmic localization of IB (Fig. 2B,
upper panels). However treatment with LMB resulted in nuclear accu-
mulation of basal and newly synthesized IB, as reflected by coincident
stainingwithDAPI-stained nuclei (Fig. 2B, lower panels). The combined
approaches of subcellular fractionation and confocal microscopy
strongly indicate that IL-1 can induce IB that is capable of translo-
cating to the nucleus.
Although newly synthesized IB is capable of nuclear accumulation,
NFB remains bound to DNA thus raising the possibility that newly
made IB undergoes some in vivomodification that prevents an inter-
action with DNA-bound NFB. Co-immunoprecipitation studies were
FIGURE 1. IL-1 induces long termpersistent activation of NFB in 1321N1 astrocy-
tomas. 1321N1 astrocytomas were treated with or without IL-1 (10 ng/ml) for the
indicated time periods. A, nuclear extracts (10g of protein) were assessed for the pres-
ence of NFB DNA binding activity by EMSA. B, nuclear extracts from cells, treated for
24 h with IL-1, were preincubated with anti-p65 or nonimmune (IgG) antibody before
assessingNFBDNAbinding activity.C, cytosolic extracts (20gprotein)were prepared
and analyzed by Western immunoblotting for levels of IB and IB. These results are
each representative of three independent experiments.
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employed to evaluate this possibility. 1321N1 astrocytomas were
treated with or without IL-1 for 10 min or 1 h. Cell lysates and the
corresponding anti-p65 immunoprecipitates were analyzed by SDS-
PAGE and subsequentWestern immunoblotting for p65 and IB. Lev-
els of p65 were constant in both cell lysates and immunoprecipitates
(Fig. 2C, upper panel). IBwas fully degraded after 10min of treatment
with IL-1 (Fig. 2C, lower panel, lanes 2 and 6). After 1 h of treatment
with IL-1, IB had returned to control levels (Fig. 2C, lower panel,
lane 8) and, significantly, was capable of interacting with p65 as evi-
denced by co-immunoprecipitation of p65 and newly synthesized IB
FIGURE 2. IB, resynthesized following IL-1
stimulation, can enter the nucleus and interact
with p65 in 1321N1s. 1321N1 astrocytomaswere
stimulated with or without IL-1 (10 ng/ml) for 30
min before treatment with LMB (10 nM) for a fur-
ther 3 h. A, cytosolic (C) and nuclear (N) extracts
(20 g) were prepared and analyzed by Western
immunoblotting for levels of IB. B, the subcellu-
lar localization of IB was assessed by indirect
immunofluorescence using anti-IB rabbit poly-
clonal antibody and Texas Red-conjugated anti-
rabbit secondary antibody. Nuclei were stained
with DAPI, and confocal images were captured
using the63 objective (oil immersion) on the UV
Zeiss 510 Meta System laser scanning microscope
equipped with the appropriate filter sets. Data
analysis was performed using the LSM 5 browser
imaging software. C, 1321N1 astrocytomas were
stimulated with or without IL-1 (10 ng/ml) for 10
min or 1 h. Cell lysates were generated and immu-
noprecipitated (IP) with anti-p65 antibody. Cell
lysates and corresponding immunoprecipitates
were subjected to Western immunoblotting to
measure levels of p65 and IB. The above results
are each representative of three independent
experiments.
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(Fig. 2C, lower panel, lane 4). This finding strongly indicates that resyn-
thesized IB can enter the nucleus and interact with NFB complexes
containing p65. However, the sustained activation of NFB, as evi-
denced by the persistent presence of p65 complexes in EMSA analysis,
suggests that although newly synthesized IB can translocate to the
nucleus and interact with p65, it is apparently incapable of terminating
the prolonged DNA binding activity of NFB. Thus, newly synthesized
IBwas next examined for its ability to promote relocation of p65 from
the nucleus to the cytoplasm.
IL-1-induced IBMediates the Nuclear Export of NFB in 1321N1
Astrocytoma—Tomonitor the localization of p65, a confocal microsco-
py-based approach was developed. This was initially used to character-
ize the time-dependent distribution of p65 in response to IL-1 stimu-
lation. 1321N1 astrocytomas were stimulated with IL-1 for various
time periods, and the localization of endogenous p65 was assessed by
indirect immunofluorescence. In resting cells, p65 is predominantly
cytoplasmic, as evidenced by the detection of Texas Red-conjugated
immunocomplexes outside of the DAPI-stained regions (Fig. 3A). The
stimulation of cells with IL-1 for 30 min caused a pronounced accu-
mulation of p65 in the nucleus, and this remained for at least 1 h. How-
ever, 3 h following stimulation, p65 had undergone significant redistri-
bution to the cytoplasm, although residual levels were still detectable in
the nuclei of some cells. This predominant cytoplasmic distribution
with residual presence in the some nuclei was still observed 8 and 24 h
after IL-1 treatment. To assess a potential role for resynthesized IB
in the export of p65, the sensitivity of the CRM1 receptor to LMB was
again exploited. 1321N1 astrocytomas were treated with IL-1 for 30
min prior to addition of LMB for a further 2.5 h. LMB alone caused the
partial accumulation of p65 in the nucleus (Fig. 3B, lower left panel). As
mentioned above, IB-NFB complexes undergo nucleocytoplasmic
shuttling in the resting state, as IB onlymasks one of the two available
NLSs of the NFB dimer. Thus, this accumulation most likely resulted
from the export of shuttling complexes being inhibited. When LMB
treatment was preceded by IL-1 stimulation, a more complete nuclear
accumulation of p65was observed (Fig. 3B, lower right panel). The effect
of LMB treatment on p65 localization, post-IL-1 stimulation, indicates
that the redistribution of p65 to the cytoplasm following IL-1 treat-
ment is CRM1-dependent and likely IB-dependent.
Further evidence supporting the ability of newly synthesized IB to
remove NFB from the nucleus was obtained using cycloheximide
(CHX), a potent inhibitor of protein synthesis (34). 1321N1 astrocyto-
mas were treated with or without CHX for 1 h before stimulation in the
presence or absence of IL-1 for an additional 3 h. Inhibition of protein
synthesis prior to IL-1 stimulation blocks the resynthesis of IBwith-
out affecting levels of p65, as shown by Western immunoblotting of
whole cell extracts (Fig. 4A). The lack of new IB synthesis in the
presence of CHX was also demonstrated by indirect immunofluores-
cence (Fig. 4B). The localization of p65 in the presence and absence of
resynthesized IB was then examined. As shown above, p65 largely
redistributes to the cytoplasm 3 h after IL-1 treatment (Fig. 4C, upper
right panel). However no such relocation is seen when IL-1 addition is
preceded by treatment with CHX. In the absence of IB to mediate
export, p65 remains in the nucleus (Fig. 4C, lower right complex). It
should be noted that the shorter half-life of IB relative to Rel subunits
can result in NFB activation with prolonged inhibition of protein syn-
thesis. Although a small amount p65 was detected in the nuclei of some
CHX-treated cells compared with control cells, CHX itself was not
believed to have had amajor effect onNFB activation over the 4-h time
course of this experiment.
These data indicate that IL-1 can induce resynthesis of IB that
translocates to the nucleus, interacts with p65, and promotes the
nuclear export of p65 complexes. However, the newly synthesized IB
fails to fully terminate the activation of NFB as indicated by persistent
residual levels of nuclear p65 in the EMSA and confocal microscopy
analysis. We envisaged that the sustained nuclear presence of p65 may
be because of some p65 complexes that are refractory to inhibition by
IB or alternatively that continuous flux through the IL-1 signaling
FIGURE 3. p65 undergoes partial redistribution to the cytoplasm following IL-1
stimulationof1321N1astrocytomas. Indirect immunofluorescencewas conducted to
assess the subcellular localization of p65 in 1321N1 astrocytomas following treatment
with orwithout IL-1 (10 ng/ml) for the indicated time periods (A), or stimulationwith or
without IL-1 (10 ng/ml) for 30minprior to treatmentwith LMB (10 nM) for a further 2.5 h
(B). Nuclei were stained with DAPI, and confocal images were captured using the 63
objective (oil immersion) on the UV Zeiss 510 Meta System laser scanning microscope
equipped with the appropriate filter sets. Data analysis was performed using the LSM 5
browser imaging software. The above results are each representative of three independ-
ent experiments.
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pathway leads to sustained degradation of some of the newly synthe-
sized IB and allows for persistent translocation of NFB into the
nucleus. The latter hypothesis was next addressed.
Long Term Activation of NFB in 1321N1 Astrocytoma Is Caused by
Persistent Signaling from the IL-1 Receptor—To measure the flux
through the IL-1 signaling pathway over time, the phosphorylation sta-
tus of IB during the course of sustainedNFB activity in 1321N1 cells
was examined. Whole cell extracts were generated, and IB was
probed for phosphorylation status at serine residues 32 and 36. (Ser-32/
36) (Fig. 5A). Phosphorylated IB was detected 5 min following treat-
ment with IL-1. IB was absent from cells at 30 min but reappeared
by 1 h. This resynthesized IB was subject to phosphorylation, and
phospho-IBwas detected up to 24 h after IL-1 stimulation, albeit at
lower levels than at 1 h. To assess the activity of the IKK complex at
these time points, IKK was immunoprecipitated from 1321N1 astro-
cytoma previously stimulated with or without IL-1, and incubated in
kinase buffer with recombinant IB. Phosphorylation of the substrate
on serines 32 and 36was thenmeasured (Fig. 5B). Activity of the enzyme
was increased after a 5-min treatment of cells with IL-1 and remained
elevated for 1 h. By 3 h, IKK activity had declined. However, at 8 and
24 h, IKK activity was higher than basal levels. The detection of endog-
enous phospho-IB and IKK activity 24 h following IL-1 stimula-
tion strongly indicates that IL-1 causes activation of its signal trans-
duction pathway in a persistent manner, leading to long term activation
of the IKK enzyme complex, continuous phosphorylation and degrada-
tion of IB, and sustained activation of NFB.
We next attempted to interfere with the persistent nature of the IL-1
signaling pathway to confirm that prolonged triggering of the pathway is
responsible for sustained activation of NFB. IL-1 receptor antagonist
(IL-1ra) was added to the cells 1 h post-IL-1 treatment, thereby allow-
ing initial activation of the IKK pathway. Levels of endogenous phos-
pho- and total IB were again measured from whole cell extracts. As
before, phosphorylation of IB on serines 32 and 36 was observed 8 h
after stimulationwith IL-1 (Fig. 6A, lane 2). However, when IL-1rawas
added post-IL-1 treatment, phospho-IB was undetectable at 8 h
(Fig. 6A, lane 3). IL-1ra alone had no effect on endogenous levels of the
protein (Fig. 6A, lane 5). Thus, IL-1ra terminated the long term phos-
phorylation of IB. This has important functional consequences
because similar treatment of cells with IL-1ra 1 h post-IL-1 stimula-
FIGURE 4. Nuclear export of p65 requires IB resynthesis in 1321N1 astrocytomas
following IL-1 stimulation. 1321N1 astrocytomaswere treatedwith or without IL-1 (10
ng/ml) for 3 h in the presence or absence of CHX (10g/ml). Western immunoblottingwas
performedonwhole cell extracts tomeasure levels of IB, p65, and-actin (A). The subcel-
lular localization of IB (B) and p65 (C) was determined by indirect immunofluorescence.
Nucleiwere stainedwithDAPI, and confocal imageswere capturedusing the63objective
(oil immersion) on theUV Zeiss 510Meta System laser scanningmicroscope equippedwith
the appropriate filter sets. Data analysis was performed using the LSM 5 browser imaging
software. The above results are each representative of three independent experiments.
FIGURE 5. The IL-1 signaling pathway is persistently activated by IL-1 stimulation
in 1321N1 astrocytomas. 1321N1 astrocytomas were stimulated with or without IL-1
(10 ng/ml) for the indicated time periods. A, whole cell extracts were generated and
probed for levels of phospho-IB (Ser-32/36), total IB, and-actin byWestern immu-
noblotting. B, cell lysates were immunoprecipitated with anti-IKK antibody. Immuno-
precipitates were incubated with recombinant IB in kinase buffer and subjected to
Western immunoblotting using anti-phospho-IB (Ser-32/36) antibody. These results
are representative of three independent experiments.
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tion causes strong inhibition of IL-1 induction of the NFB-regulated
chemokine, IL-8 (Fig. 6C). These data strongly suggest that persistent
triggering of the IL-1 receptor by IL-1 causes continuous activation of
IKK, leading to phosphorylation and degradation of IB, and allowing
for sustained activation of NFB and chronic induction of NFB-re-
sponsive genes. This model is further supported by the use of MG132,
an inhibitor of the 26 S proteasome. The addition of MG132 1 h post-
IL-1 stimulation caused considerable accumulation of phospho-IB
at 8 h (Fig. 6A, compare lanes 2 and 4), strongly confirming continuous
activation of IKK and phosphorylation of IB in response to persistent
triggering of the pathway by IL-1. Prolonged IL-1 signaling and IB
degradation are required to maintain chronic NFB activation, as pro-
teasome inhibition post-IL-1 stimulationwas found to reduce the level
ofNFBDNAbinding activity (Fig. 6B). Furthermore, like IL-1ra, inhib-
iting this persistent signaling with MG132 strongly attenuates the long
term induction of IL-8 by IL-1 (Fig. 6C). These findings demonstrate
that the continuous binding of IL-1 to its astrocyte receptor leads to
persistent phosphorylation and degradation of IB, resulting in sus-
tained activation of NFB.
IL-1 Causes Sustained Activation of NFB in a Promoter-specific
Manner in Astrocytes—The previous EMSA and confocal studies dem-
onstrated that IL-1 causes peak activation ofNFB at 1 h, and although
nuclear localization and DNA binding decreases over time, it is still
sustained at 24 h. We finally addressed if this temporal regulation was
the same for all NFB-responsive promoters. The EMSA procedure
provides information on the DNA binding activity of the global popu-
lation of NFB, but it does not examine the presence of NFB on indi-
vidual promoters and ignores the impact of chromatin structure on
FIGURE 6. IL-1 signaling inhibitors, post-IL-1
stimulation, attenuate the persistent activa-
tion of NFB in 1321N1 astrocytomas. 1321N1
astrocytomas were stimulated with or without
IL-1 (10 ng/ml) for 8 h. 1 h post IL-1 addition,
cells were treated with or without IL-1ra (200
ng/ml) or MG132 (10M). A, 1321N1 astrocytomas
were grown to confluency in 6-well plates; whole
cell extracts were generated, and levels of phos-
pho-IB (Ser-32/36), total IB, and -actin were
determined by Western immunoblotting. The
results shown are each representative of three
independent experiments. B, 1321N1 astrocyto-
mas were grown to confluency in 25-cm2 flasks.
Nuclear extracts (10 g of protein) were assessed
for the presence of NFB DNA binding activity by
EMSA. The results shown are each representative
of three independent experiments. C, 1321N1
astrocytomasweregrown to confluency in 96-well
plates, and themediumwas removed and assayed
for IL-8 levels by sandwich enzyme-linked immu-
nosorbent assay. Results are expressed as concen-
tration of IL-8 in pg/ml. Data are presented as the
mean  S.E. of three independent experiments.
**, p  0.01; ***, p  0.001 versus sample treated
with IL-1 alone (unpaired t test).
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DNA-binding ability. Chromatin immunoprecipitation studies were
therefore performed to monitor the presence of p65 at the IL-8 and
ICAM-1 promoters in 1321N1 astrocytomas previously stimulated with
or without IL-1 for 1 or 24 h. SDS-PAGE and Western immunoblot-
ting of anti-p65 and control IgG immunoprecipitates from nuclear
extracts demonstrated the presence of nuclear p65 both 1 and 24 h after
IL-1 treatment (Fig. 7A). Analysis of immunoprecipitated DNA by
PCR indicated that p65 was present at both the IL-8 and ICAM-1 pro-
moters 1 h post-stimulation with IL-1 (Fig. 7B). However, 24 h after
stimulation, it was detected only at the IL-8 promoter. This was con-
firmed by quantitative real time PCR analysis of the immunoprecipi-
tated DNA, where a statistically significant level of p65 binding was
recorded at the IL-8, but not ICAM-1, promoter at the later time point
(Fig. 7C). GAPDH promoter was not detected in p65-immunoprecipi-
tates, demonstrating the specificity of IL-8 and ICAM-1 promoter
enrichment (Fig. 7B). Thus the sustained activation of NFB by IL-1 in
astrocytes is promoter-specific. Finally, we addressed the functional
consequence of this promoter-specific effect by quantitating levels of
mRNA encoding IL-8 and ICAM-1 by real time PCR and assessing how
their induction by IL-1 varied over time. IL-1 caused an 175-fold
induction of IL-8mRNA in 1321N1 cells at 3 h, and this wasmaintained
above 100-fold at 24 h (Fig. 8A). ICAM-1 mRNA was induced over
FIGURE 7. IL-1 causes differential temporal
profiles of p65 binding to B-responsive pro-
moters in 1321N1 astrocytomas. 1321N1 astro-
cytomas were treated with or without IL-1 (10
ng/ml) for the indicated time periods. Nuclear
lysates were generated and immunoprecipitated
(IP) with anti-p65 or control IgG antibodies. A, fol-
lowing SDS-PAGE, immunoprecipitates were sub-
jected to Western immunoblotting with anti-p65
antibody. Immunoprecipitated DNAwas analyzed
for IL-8, ICAM-1, and GAPDH promoters by PCR
andgel electrophoresis (B) and for IL-8 and ICAM-1
promoters by quantitative real time PCR (C). Data
from real time PCR are expressed as fold differ-
ences between DNA enrichment in the anti-p65
ChIP sample relative to IgG ChIP sample and are
displayed as the means  S.E. from three inde-
pendent experiments. *, p  0.05; ***, p  0.001
versus control at 0 h (unpaired t test).
FIGURE 8. IL-1 induces sustained production of
IL-8 mRNA, but transient induction of ICAM-1
mRNA, in 1321N1 astrocytomas. 1321N1 astrocy-
tomaswere treatedwith orwithout IL-1 (10 ng/ml)
for the indicated timeperiods. RNAwas isolated and
converted into cDNA. Samples were assayed by
quantitative real time PCR for levels of IL-8 (A) and
ICAM-1 (B)mRNAusing theABI PRISM7900HT ther-
mal cycler. Data are expressed as mRNA induced by
IL-1 treatment normalized to a time-matched con-
trol and are displayed asmeans from two independ-
ent experiments.
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300-fold by 3 h of stimulation with IL-1. However, in contrast to IL-8,
the levels of ICAM-1 mRNA decreased almost to control levels by 24 h
(Fig. 8B). It is highly likely that the sustained expression of IL-8 mRNA
is because of the prolonged presence of p65 on the IL-8 promoter,
whereas transient association of p65 with the ICAM-1 promoter closely
correlates with short lived induction of ICAM-1 mRNA.
DISCUSSION
Although leukocyte extravasation is a necessary response to patho-
genic invasion, chronic or aberrant inflammation underlies numerous
disease states. Increased expression of molecules mediating inflamma-
tion is seen in various disorders of the CNS. Studies onMS and on EAE
have demonstrated the positive correlation of pro-inflammatory cyto-
kine expression with disease progression (15, 22). ICAM-1 expression is
up-regulated in MS and EAE, where it is expressed on astrocytes and
microglia in addition to endothelial cells (35, 36). Efficient suppression
of EAE has been achieved by treatment with anti-ICAM-1 monoclonal
antibody (37). Furthermore, studies on disease progression and remis-
sion in EAE animals indicate that the T-lymphocyte entry into and
subsequent departure from the CNS is coincident with increased and
decreased expression of pro-inflammatory cytokines and ICAM-1 (36,
38). IL-8 is also expressed in EAE animals during disease onset (38), but
as a chemoattractant acting predominantly on neutrophils, it appears to
have a more important role in conditions such as bacterial meningoen-
cephalitis and cerebral reperfusion/ischemia injury where there is a sig-
nificant neutrophilic contribution to the CNS lesion (39–41). In terms
of controlling the cerebral recruitment of leukocytes and the ensuing
neuropathogenesis, an increased understanding of themechanisms reg-
ulating the expression of adhesionmolecules, like ICAM-1, and chemo-
kines, like IL-8, in resident brain cells will be of great import.
Regulation of gene expression commonly occurs at the level of tran-
scription. The inducible transcription factor NFB plays a key role in
controlling the transcription of many immune and inflammatory
response genes including adhesion molecules and chemokines (2).
IL-1 has been shown previously to activate NFB in glial cells, leading
to the expression of IL-8 and ICAM-1 (23, 24). The rapid inducibility of
the NFB pathway is undoubtedly beneficial for immune response to
infection or injury. However, long term activation of the transcription
factor has been observed in chronic inflammatory disease states includ-
ing rheumatoid arthritis, asthma, andMS (14, 16). Given the central role
of NFB in the pathogenesis and maintenance of these chronic inflam-
matory states, the importance of examining the mechanisms behind its
sustained activation is clear. Some such mechanisms have been eluci-
dated. Agents causing long term activation of NFB are known to cause
degradation of IB in addition to IB (13). In pre-B-cells stimulated
with LPS or IL-1, IB is degraded and resynthesized in a hypophos-
phorylated form, which binds NFBwithout inhibiting nuclear translo-
cation or DNA binding. Within this complex, NFB is refractory to
inhibition by resynthesized IB (26). The same mechanism is respon-
sible for the continuous activation of NFB in early mature B-cells (42).
This group has shown previously that IL-1 stimulation of glial cells
causes long term, persistent activation of NFB (25). As IB remained
absent over the course of sustained NFB activity, the question arose as
to how IB failed to terminate this activity upon resynthesis. Here we
show that IB is able to enter the nucleus upon resynthesis, as evi-
denced by its accumulation in that compartment after IL-1 treatment
under conditions where nuclear export is inhibited. Co-immunopre-
cipitation studies revealed that resynthesized IB is able to interact
with p65, although indirect immunofluorescence indicated that the
majority of p65-containing NFB dimers are returned to the cytoplasm
3 h post-IL-1 stimulation. The apparent discrepancy between the abil-
ity of IB tomediate some degree of post-induction repression and the
persistent presence of NFB DNA binding activity were resolved by
assessing the temporal profile of the IL-1 signaling cascade. IB, phos-
phorylated on serines 32 and 36, was detected up to 24 h following initial
IL-1 stimulation. Furthermore, in vitro kinase assays demonstrated
that IKK, the enzyme responsible for the inducible phosphorylation,
was still active at this late time point. As NFB-bound IB constitutes
a better substrate for IKK than free IB (43), the phosphorylated form
of the protein detectedmost likely represents IB that has been resyn-
thesized and has returned NFB to the cytoplasm before becoming
subject to further degradation.
That the persistent activation of NFB observed in these glial cells
was dependent on continuous IL-1 signaling was verified using IL-1
receptor antagonist. When applied post-IL-1 stimulation to allow ini-
tial NFB activation, IL-1ra inhibited the IKK-mediated phosphoryla-
tion of IB. It also attenuated the IL-1-induced production of IL-8, a
process dependent on NFB transcriptional activity. The latter effect
was also achieved through inhibition of the 26 S proteasome using
MG132. The signaling and proteasome dependence of sustained NFB
activity indicates that there is persistent IKK activation and breakdown
of IB following IL-1 stimulation. IB remains absent at the protein
level despite the continued presence of the mRNA transcript (25). It is
possible that IB protein is subject to immediate degradation upon
resynthesis. Unlike IB, IB expression is not induced by NFB
activation (13). Therefore, the low level of basal production in these
cells may not be sufficient to overcome the IL-1-mediated protein
breakdown.
The in vivo recruitment of NFB to two immunologically relevant,
B-responsive promoters, IL-8 and ICAM-1, was analyzed by chroma-
tin immunoprecipitation studies. The Rel subunit chosen for detection
for ChIP studies, as for indirect immunofluorescence, was p65 because
of its transactivating ability (44). Furthermore, the predominant forms
of NFB activated in these cells are p65-p50 heterodimers and p65
homodimers (25). Finally, the variant B sites in both the IL-8 and
ICAM-1 promoters are known to recruit p65 homodimers following
NFB activation (18, 19). ChIP studies revealed that p65 is found at both
promoters 1 h following IL-1 stimulation, but only at the IL-8 pro-
moter after 24 h IL-1. This confirms the finding of other groups that
the overall NFB-DNA binding activity as assessed by EMSA does not
necessarily reflect the in vivo binding of NFB to specific promoters
(45). The transcriptional activationmediated byNFB at these promot-
ers was examined by quantitative real time PCR analysis of IL-8 and
ICAM-1 mRNA levels. In line with ChIP data, divergence in the IL-1-
mediated induction of ICAM-1 and IL-8 gene expression was observed.
Although ICAM-1 mRNA had returned almost to control levels 24 h
after IL-1 treatment, IL-8 expression was still up-regulated.
A large degree of similarity exists between the IL-8 and ICAM-1
promoters. The form of NFB that binds preferentially to the B sites of
both promoters is the p65 homodimer, and NFB binding is essential
for IL-1-mediated gene induction. In both cases, binding occurs to a
variant B site that lacks the run of three or four consecutive guanine
residues required for p50 binding at the 5 end (18, 19). The sequence of
the IL-8 B site is in fact identical to the ICAM-1 B site except for an A
to T transition in the center of the decameric sequence. The nucleotides
immediately flanking theB site in the ICAM-1promoter appear to play
an important role in NFB binding and transactivation, with the mini-
mal ICAM-1-B site incapable of supporting tumor necrosis factor--
mediated induction when placed upstream of a reporter gene (46).
However, a similar situation does not seem to exist in the IL-8 promoter
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(47). Both promoters also contain adjacent C/EBP-binding sites in their
5-flanking region, adjacent to the B sites. IL-1-mediated transcrip-
tional activation is regulated by cooperative effects between C/EBP and
NFB. In the IL-8 promoter C/EBP and NFB binding occurs cooper-
atively, with resulting synergistic activation of IL-8 gene expression (17).
However, there are conflicting reports on the outcome of this interac-
tion on the ICAM-1 promoter, with one study demonstrating that
C/EBP attenuated the transactivating effects of p65 on ICAM-1
expression in primary astrocytes (48). Thus, although the Rel binding
characteristics and identity of cis-acting elements in the IL-8 and
ICAM-1 promoters are similar, differences exist that could contribute
to the persistence of p65 at one but not the other. Selective binding of
NFB to a subset of target promoters has been demonstrated previously
in macrophages (45). In this case, NFB was shown to bind to certain
promoters immediately upon entering the nucleus following activation.
Recruitment occurred later at other target sites, where stimulus-de-
pendent alterations of promoter acetylation status may have been
required. Promoter accessibility is therefore another level of control of
NFB activity. Diverse affinity of NFB for the B sites, interaction with
other trans-acting factors, and modified promoter accessibility could
account for the sustained presence of p65 at the IL-8 but not ICAM-1
promoter. It is also possible that newly synthesized IB is capable of
removing NFB from the ICAM-1 promoter, whereas the IL-8 promot-
er-bound transcription factor remains refractory to the post-induction
repression. The persistent presence of NFB on a subset of target pro-
moters following IL-1 synthesis has been proposed previously to be
due to the presence of hypophosphorylated IB in a complex with
DNA-bound NFB (45). However, IB does not reappear at the pro-
tein level in IL-1-stimulated astrocytes, ruling out this mechanism.
In summary, we have shown that persistent IL-1 signaling in an
astrocytic cell system leads to sustainedNFB activity despite the ability
of newly synthesized IB to remove NFB from the nucleus. Over the
course of this long term NFB activation, there is an alteration of the
profile of B-responsive promoters at which the transcription factor
persists, leading to differential expression of target genes. This signifi-
cantly advances our molecular appreciation of the mechanisms under-
lying chronicNFB activation in glial cells and provides important clues
for informing new therapeutic strategies in the treatment of neuro-
pathological conditions.
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